118 related articles for article (PubMed ID: 25185694)
21. High-dose interferon and the U.K. guidelines for cutaneous melanoma.
Russell-Jones R; Healy C; Calonje E; Doherty M; Acland K
Br J Dermatol; 2002 Oct; 147(4):832-4; author reply 834-5. PubMed ID: 12366454
[No Abstract] [Full Text] [Related]
22. Update on adjuvant interferon therapy for high-risk melanoma.
Agarwala SS; Kirkwood JM
Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
[TBL] [Abstract][Full Text] [Related]
23. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
Ockenfels M; Lisch W
Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
[TBL] [Abstract][Full Text] [Related]
24. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
25. Care of the patient undergoing interferon therapy.
Garvey EC; Matutat RJ; Bolten D
Cancer Nurs; 1983 Aug; 6(4):303-6. PubMed ID: 6192903
[No Abstract] [Full Text] [Related]
26. Malignant melanoma (non-metastatic).
Crosby T; Mason M; Savage P
Clin Evid; 2004 Dec; (12):2321-35. PubMed ID: 15865791
[No Abstract] [Full Text] [Related]
27. Malignant melanoma (non-metastatic).
Crosby T; Mason M; Savage P
Clin Evid; 2003 Dec; (10):1897-909. PubMed ID: 15555184
[No Abstract] [Full Text] [Related]
28. Melanoma vaccines: possible progress after years of frustration?
Schmidt C
J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
[No Abstract] [Full Text] [Related]
29. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
30. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
Korovin SI
Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
[TBL] [Abstract][Full Text] [Related]
31. Malignant melanoma (non-metastatic).
Crosby T; Mason M; Savage P
Clin Evid; 2005 Dec; (14):2058-72. PubMed ID: 16620482
[No Abstract] [Full Text] [Related]
32. Interferon (IFN) for malignant melanoma unmasking an autoimmune hepatitis.
Lebiedz P; August C; Domschke W; Schmidt HH
Eur J Intern Med; 2009 Jan; 20(1):e3-4. PubMed ID: 19237078
[No Abstract] [Full Text] [Related]
33. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
34. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review.
Larkin JM; Fisher RA; Gore ME
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):410-2. PubMed ID: 22521078
[No Abstract] [Full Text] [Related]
36. Adjuvant interferon: extended follow-up times needed?
Thoren FB; Strannegård Ö
Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
[No Abstract] [Full Text] [Related]
37. Adjuvant Therapy in High-Risk Stage III Cutaneous Melanoma.
Barker CA
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):11-12. PubMed ID: 28586947
[No Abstract] [Full Text] [Related]
38. Delayed wound healing following treatment with low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury AF; El Sayed F; Bazex J
Arch Dermatol; 2007 Oct; 143(10):1339-40. PubMed ID: 17938359
[No Abstract] [Full Text] [Related]
39. The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eggermont AMM; Dummer R
Eur J Cancer; 2017 Nov; 86():101-105. PubMed ID: 28968566
[TBL] [Abstract][Full Text] [Related]
40. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
